Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total homocysteine from baseline
Pegtibatinase has been generally well-tolerated to date
The Company is engaging with regulators and expects to initiate a pivotal Phase 3 Study by year-end 2023
Company to host conference call and webcast today at 8.30 a.m. ET
Travere Therapeutics will host a conference call and webcast today, Wednesday, May 31, 2023, at 8:30 a.m. ET to discuss the topline results from cohort 6 in the Phase 1/2 COMPOSE Study. To participate in the conference call, dial +1 (888) 394-8218 (U.S.) or +1 (323) 994-2093 (International), confirmation code 7036007. The webcast can be accessed on the Investor page of Travere’s website at ir.travere.com/events-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.
https://finance.yahoo.com/news/travere-therapeutics-announces-positive-topline-110000227.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.